<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01030211</url>
  </required_header>
  <id_info>
    <org_study_id>TTSH ADEPT</org_study_id>
    <nct_id>NCT01030211</nct_id>
  </id_info>
  <brief_title>Adult Dengue Platelet Study</brief_title>
  <acronym>ADEPT</acronym>
  <official_title>Adult Dengue Platelet Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tan Tock Seng Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Singapore General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Changi General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National University Hospital, Singapore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Malaya</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tan Tock Seng Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retrospective data in children with dengue hemorrhagic fever (DHF) and dengue shock syndrome
      (DSS), and in adults with dengue fever (DF), suggested a lack of benefit from prophylactic
      platelet transfusion for severe thrombocytopenia in dengue patients without bleeding.
      However, in Taiwan and Singapore, platelet transfusion was given to 13-50% of hospitalised
      dengue patients. This is a prospective randomised study to examine the safety and efficacy of
      prophylactic platelet transfusion in adults with dengue and severe thrombocytopenia without
      bleeding.

      The hypotheses are:

        1. Prophylactic platelet transfusion is safe in hospitalised dengue patients with severe
           thrombocytopenia.

        2. Prophylactic platelet transfusion is effective in preventing bleeding in hospitalised
           dengue patients with severe thrombocytopenia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients fulfilling inclusion and exclusion criteria, and giving informed consent, will be
      randomised to a treatment arm of 4 units of platelets for every day they have a platelet
      count &lt;20x10^3/uL, or a control arm with supportive care. Patients will be followed up daily
      till hospital discharge, and again at day 21.

      It is assumed that the incidence of bleeding from randomization to Day 7 or discharge,
      whichever earlier, is 10% for the control (no transfusion) group and 5% for the intervention
      (transfusion) group. With 1:1 allocation ratio, to attain 80% power and one-sided 5% type I
      error rate, the required number of subjects in each arm is 382 by a Chi-square test with
      Yates' continuity correction. If a drop-out rate of 5% is allowed, the required number
      increases to approximately 400 per arm.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical bleeding excluding petechiae with a subgroup analysis for severe clinical bleeding.</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Platelet increment post-transfusion</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to platelet &gt; 50 x 10^3/uL</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in cytokines</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma leakage</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DHF/DSS</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU admission</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary bacterial infection</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events from transfusion</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">372</enrollment>
  <condition>Dengue Fever</condition>
  <arm_group>
    <arm_group_label>Platelet transfusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 units of platelets for patients with platelet count &lt;20x10^3/uL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Supportive care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>No platelet transfusion for patients with platelet count &lt;20x10^3/uL</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Platelet transfusion</intervention_name>
    <description>4 units of platelets for patients with platelet count &lt;20x10^3/uL</description>
    <arm_group_label>Platelet transfusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Supportive care</intervention_name>
    <description>Supportive care includes symptomatic treatment, fluid therapy and monitoring of full blood count and blood pressure</description>
    <arm_group_label>Supportive care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 21years

          2. Probable or confirmed dengue

             a) Confirmed dengue: laboratory confirmation of acute dengue by either i) positive
             polymerase chain reaction (PCR) for viral ribonucleic acid (RNA), or ii)positive NS1
             antigen test with a compatible clinical syndrome b) Probable dengue: Positive acute
             dengue serology and clinical presentation fulfilling either WHO 1997 or 2009 criteria
             for probable dengue.

             i) 1997 criteria: Acute febrile illness and two or more of the following:

               -  headache,

               -  retro-orbital pain,

               -  myalgia,

               -  arthralgia,

               -  rash,

               -  hemorrhagic manifestations,

               -  leucopoenia ii) 2009 criteria: Fever and two of the following:

               -  nausea/vomiting,

               -  rash,

               -  aches/pains,

               -  positive tourniquet test,

               -  leucopoenia,

               -  one or more warning sign

               -  abdominal pain/tenderness,

               -  persistent vomiting,

               -  clinical fluid accumulation,

               -  mucosal bleed,

               -  lethargy/restlessness,

               -  liver enlargement &gt;2cm,

               -  increase in haematocrit concurrent with rapid decrease in platelet count

          3. Platelets ≤ 20x103/μL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yee S Leo, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tan Tock Seng Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Malaya Medical Centre</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tan Tock Seng Hospital, National University Health System, Singapore General Hospital, Changi General Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Malaysia</country>
    <country>Singapore</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2009</study_first_submitted>
  <study_first_submitted_qc>December 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2009</study_first_posted>
  <last_update_submitted>August 23, 2015</last_update_submitted>
  <last_update_submitted_qc>August 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tan Tock Seng Hospital</investigator_affiliation>
    <investigator_full_name>David Lye</investigator_full_name>
    <investigator_title>Dr David Lye</investigator_title>
  </responsible_party>
  <keyword>Dengue</keyword>
  <keyword>Platelet transfusion</keyword>
  <keyword>Bleeding</keyword>
  <keyword>Prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dengue</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

